Key result
LCZ696 significantly improved left ventricular ejection fraction in mice with acute viral myocarditis compared to untreated AVMC mice (68.99% vs 30.95%, P<0.05).
Why the study?
Acute viral myocarditis has few specific treatments, and while LCZ696 improves LVEF in heart failure, limited research exists on its role in acute viral myocarditis.
Does LCZ696 improve LVEF and reduce inflammation in Coxsackievirus B3-induced acute viral myocarditis mice?
Does LCZ696 improve LVEF and reduce inflammation in Coxsackievirus B3-induced acute viral myocarditis mice?
LCZ696 protects against Coxsackievirus B3-induced acute viral myocarditis in mice by improving LVEF and reducing inflammation and apoptosis, potentially via inhibition of Drp1-mediated mitochondrial fission.
Should not change practice; hypothesis-generating for LCZ696 in murine viral myocarditis, pending human trials.
AIMS: Acute viral myocarditis (AVMC) is the aetiology of heart failure (HF) with few specific treatments. The improvement of left ventricular ejection fraction (LVEF) is a critical predictor for the prognosis of AVMC. LCZ696 is a drug used in HF to improve LVEF, with a few research on AVMC. In this research, we evaluated the effects and mechanism of LCZ696 in improving LVEF in AVMC. METHODS: Eighty 4-week-old male BALB/c mice were randomly divided into four groups of 20: Sham; Sham + LCZ696 (60 mg/kg/d); AVMC; AVMC + LCZ696. The above experiments were repeated by CVB3-infected HL-1 and Mdivi-1 to down-regulated dynamin-related protein 1(Drp1). Adeno-associated virus 9 (AAV9) with enhanced green fluorescent proteins (GFP) was injected to produce Drp1-overexpression mice and set up four groups: AVMC group, AVMC + AAV group, AVMC + LCZ696 group, and AVMC + LCZ696 + AAV group (n = 20 in each group). LVEF was evaluated by echocardiography at a similar heart rate (HR) at d7, Drp1 (p-Drp1), inflammation and apoptosis by histology and Western blot (WB), and mitochondrial by electron microscopy. RESULTS: Cardiac function were injured in AVMC that LCZ696 reversed (LVEF, %: Sham: 68.99 ± 9.67; Sham + LCZ696: 71.96 ± 6.20; AVMC: 30.95 ± 6.40*; AVMC + LCZ696: 68.99 ± 9.67*#, *P < 0.05 vs. Sham, #P < 0.05 vs. AVMC). LCZ696 attenuated p-Drp1 expression, inflammation, apoptosis, and mitochondrial fission (p-Drp1/Drp1: Sham: 1; Sham + LCZ696: 1.37 ± 0.22; AVMC: 2.29 ± 0.36*; AVMC+LCZ696: 1.43 ± 0.08*#, *P < 0.05 vs. Sham, #P < 0.05 vs. AVMC). Some of the above results were repeated in CVB3-infected HL-1 cells and Mdivi-1. AAV increased Drp1 expression and mitochondrial fission, inflammatory, and apoptosis. Compared with the AVMC + AAV group, the LVEF increased from 24.44 ± 0.03% to 32.33 ± 0.05% in the AVMC + LCZ696 + AAV group(P < 0.05), p-Drp1/Drp1 decreased from 0.54 ± 0.12 to 0.42 ± 0.09*, and IL-6, c-IL-1β, and c-caspase-3/caspase-3 decreased from 1.07 ± 0.22 to 0.72 ± 0.08*, from 1.03 ± 0.14 to 0.79 ± 0.09*, and from 4.69 ± 0.29 to 0.92 ± 0.13*, respectively (*P < 0.05). CONCLUSIONS: LCZ696 has a protective effect on AVMC by improving LVEF and reducing inflammation and apoptosis, which may be due to the inhibition of Drp1-mediated mitochondrial fission.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) studied Acute viral myocarditis (n=80). LCZ696 vs. AVMC without LCZ696 was evaluated on Left ventricular ejection fraction (LVEF) (p=< 0.05). LCZ696 significantly improved left ventricular ejection fraction in mice with acute viral myocarditis compared to untreated AVMC mice (68.99% vs 30.95%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: